Imugene Appoints Leading Biotechnology Executive and Entrepreneur-Dr Jens Eckstein
Imugene Limited (ASX: IMU) is a clinical stage immuno-oncology firm. The company is developing a range of new and novel immunotherapies that basically activates...
Imugene Limited Provided Quarterly Cash Flow Report For March Quarter
Biotechnology company, Imugene Limited (ASX: IMU) is an emerging leader in cancer immuno-oncology which has made significant progress in the recent past. Today, the...
Imugene released research study of PD-1 mimotope cancer vaccine
Imugene Limited (ASX: IMU) is a biotechnology company, having operations in America and Europe is working specifically in the clinical stage of immuno-oncology. Immuno-oncology...
Imugene Presented New Data On the KEY-Vaxx & B-Vaxx Cancer Vaccine
Imugene Limited (ASX: IMU) is an immuno-oncology company, which is into the clinical stage. The company is engaged in the operations of developing a...
Imugene provides Guidance for KEY-Vaxx Cancer Immunotherapy
Imugene Limited (ASX: IMU) is an ASX listed biotechnology company based in Sydney, Australia. The company’s primary focus is on the cancer immunotherapy by...
Imugene Reports Dosing Of First Patient In The HER-Vaxx Cancer Vaccine Phase 2 Study:...
Imugene Limited (ASX: IMU) is into the operations of immuno-oncology. It is in its clinical stage and is into the development of a range...
Imugene released Presentation on KEY-Vaxx and B-Vaxx Cancer Vaccine Programs for the 2019 AACR
Imugene Limited (ASX: IMU) is a biotechnology company with operations in America and Europe. The company is into the development of biologic therapies for...
Imugene’s Shares zoomed up by 17.65% on the declaration of Half-year results
Imugene Limited (ASX: IMU) has released its half-year results ended 31 December 2018. As at 31 December 2018, the group recorded a loss for...
Imugene Reported Cancer Research Publishing In The Prestigious American Journal
Imugene Limited (ASX: IMU), which is in the business of clinical stage immuno-oncology, IS building up a range of new and novel immunotherapies that...
Imugene Rebounds On Receiving Tax Rebate And Advancement To Phase 2 In Gastric Cancer...
Imugene Limited (ASX: IMU), the immuno-oncology company, with its unique technological platform basically tries to harness the immune system of the cancer patients and...
